CureGenetics

Executive Summary

CureGenetics is a clinical-stage Chinese biotechnology company pioneering first-in-class cell and gene therapies for solid tumors and genetic disorders. Leveraging its proprietary AIMS CAR-NKT platform for cell therapy and VELP™ AAV discovery platform for gene therapy, the company aims to address significant unmet medical needs in oncology and rare diseases. Founded in 2016 and headquartered in Suzhou, CureGenetics has raised approximately $93.5 million to advance its pipeline. Its lead candidate, an autologous CAR-NKT cell therapy targeting solid tumors, is currently in Phase 1 clinical trials, with initial data expected in the near term. The VELP™ platform enables engineering of novel AAV capsids for enhanced delivery, targeting genetic disorders such as inherited metabolic diseases. With a focus on innovation and a robust platform approach, CureGenetics is positioned to capitalize on the growing demand for advanced therapies in Asia and globally. However, as a private, early-stage company, it faces typical clinical and regulatory risks, and its valuation remains undisclosed. The company's progress will be closely monitored by investors interested in next-generation cell and gene therapies.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout from lead CAR-NKT program60% success
• Q4 2026IND filing for first gene therapy candidate50% success
• 2026Potential strategic partnership or licensing deal40% success